Melatonin Research: Clinical Trials, Nasal Delivery & Meta-Analysis Data
Melatonin has an expansive, gold-standard library of thousands of peer-reviewed human clinical trials, neuroimaging studies and meta-analyses. This page walks through the strongest data across nasal, sublingual and oral delivery, and what each study actually measured.
Mechanism of action
Melatonin is a principal indolamine hormone, synthesised naturally from serotonin in the pineal gland. Its two best-documented roles are regulating the human sleep-wake cycle and acting as a powerful systemic antioxidant.
As a circadian signal, melatonin is released as ambient light falls and tells the body's master clock (the suprachiasmatic nucleus) that biological night has begun. That signal lowers core body temperature and sets the timing of sleep onset — which is why the timing of administration matters as much as the amount in circadian research.
As an antioxidant, melatonin is unusual in that it crosses every cellular barrier, including cell membranes and the blood-brain barrier, and scavenges reactive oxygen species directly rather than relying on a receptor. This is the basis for the tissue-protection and oncology research strands below.
Because melatonin is highly bioavailable through several routes, the clinical literature covers oral, sublingual and intranasal (nasal spray) delivery — and the differences between them are large enough to change study outcomes.
The studies
The four research strands below cover the main directions the literature takes: circadian resetting via nasal delivery, direct cellular effects in tissue culture, systemic antioxidant protection under surgical stress, and pooled human sleep outcomes.
Intranasal reset of circadian rhythms (jet lag)
Crossing multiple time zones creates a severe circadian mismatch — daytime exhaustion paired with nighttime insomnia. This work tested whether nasal delivery can reset the clock faster than swallowing a tablet.
Intranasal (nasal spray) versus standard oral administration · pharmacokinetic tracking and circadian phase measurement
- <5 min
- Nasal Tmax
- Substantially higher
- Brain bioavailability
- ~Halved
- Jet lag recovery
time to peak absorption
vs oral
Benefits shown in the data
- Intranasal melatonin bypasses the liver's first-pass metabolism and reaches the central nervous system directly via the olfactory pathways.
- Clinical tracking recorded a rapid absorption spike with Tmax under 5 minutes, far faster than oral forms.
- That fast delivery produced an immediate drop in core body temperature and a rapid circadian phase shift, cutting jet lag recovery time roughly in half.
- The practical finding is that route changes the result: the same compound behaves very differently through the nose than through the gut.
- Phase-shifting depends on when the dose is given relative to the body clock — timing is the active variable in this research, not quantity alone.
In-vitro oncostatic and anti-tumour protection
Beyond sleep, melatonin behaves as a foundational cellular protector. This strand looks at how cancer cells behave when exposed directly to the hormone in a laboratory setting.
In-vitro cell culture assay · human hormone-dependent breast cancer cells (MCF-7) treated directly with melatonin solutions
- Significantly inhibited
- Cell proliferation
- Down-regulated
- Estrogen receptor-alpha
- Disrupted
- Microtubule structure
Benefits shown in the data
- Melatonin significantly inhibited proliferation of hormone-dependent cancer cells in culture.
- It did so by down-regulating estrogen receptor-alpha expression and disrupting the cells' internal microtubule structure.
- This demonstrates a direct cellular protective effect that has nothing to do with sleep — melatonin acts as an oncostatic agent, blocking estrogen signalling and trapping free radicals.
- Worth being clear about scope: this is isolated cells in a dish, not a treatment result. It establishes a mechanism worth studying, and it is why melatonin appears in oncology support literature — but it is not evidence that melatonin treats cancer in people.
- The estrogen-receptor finding is specific to hormone-dependent cell lines and does not generalise to all tumour types.
Systemic reduction of surgical oxidative stress
Major surgery inflicts heavy oxidative damage and ischaemia-reperfusion stress on vital organs. Researchers tested systemic melatonin as a shield for internal tissue during that window.
Systemic/subcutaneous administration in animal surgical models, paired with human clinical intravenous tracking
- Drastically lowered
- Lipid peroxidation
- Preserved
- Mitochondrial function
- Reduced
- Inflammatory cytokines
including TNF-α
Benefits shown in the data
- Melatonin crosses all cellular barriers and directly scavenges reactive oxygen species, acting as a premier free-radical scavenger.
- Systemic administration sharply lowered lipid peroxidation and preserved mitochondrial function during acute surgical stress.
- Inflammatory cytokines including TNF-α were reduced, with the protective effect observed across heart, liver and kidney tissue.
- The protection is mechanistically simple — fewer free radicals reaching tissue means less cell death — which is why the effect shows up consistently across different organs.
- Animal surgical models supply most of the tissue-level detail; the human component is largely biomarker tracking rather than hard clinical endpoints.
Meta-analysis of primary sleep disorders
Individual sleep trials are small and noisy. This pooled review gathers dozens of randomised human trials to test whether oral melatonin holds up across general populations.
Systematic meta-analysis of 19 randomised, placebo-controlled human clinical trials · 1,683 participants
- Significantly reduced
- Sleep onset latency
- Increased
- Total sleep time
- Substantially improved
- Sleep quality scores
Benefits shown in the data
- Melatonin significantly reduced sleep onset latency — the time taken to fall asleep — across the pooled trials.
- Total sleep time demonstrably increased, and sleep quality scores improved substantially across the board.
- No evidence of rebound insomnia or dependency was found, in contrast to the pattern typical of prescription sleeping pills.
- This is the strongest human evidence in the melatonin literature: randomised, placebo-controlled, and pooled across nearly 1,700 participants.
- The effect sizes are real but modest in absolute terms — melatonin shifts and stabilises sleep timing rather than sedating.
Storage & handling
Melatonin is supplied as a lyophilised powder. Keep sealed vials refrigerated or frozen, protected from light and moisture — melatonin is notably light-sensitive.
Reconstitute with bacteriostatic water added slowly down the inner wall of the vial; swirl gently until fully dissolved and never shake.
Store reconstituted solution at 2-8 °C in an opaque or foil-wrapped container, and use within your lab's defined stability window. Avoid repeated freeze-thaw cycles.
Delivery dynamics: oral vs sublingual vs nasal
The literature shows a large disparity in how the body handles different formats. This is the single most important variable when comparing melatonin studies to one another.
| Route | Bioavailability | What the research shows |
|---|---|---|
| Standard oral tablets | Only 3-15% | The liver destroys the majority of the compound via first-pass metabolism before it reaches the bloodstream, so a large share of an oral dose never becomes active. |
| Sublingual | Substantially higher than oral | Absorption through the tissue under the tongue bypasses the gut and liver entirely, dumping the hormone directly into systemic circulation. |
| Intranasal (nasal spray) | Highest, with fastest onset | Also bypasses the gut, and additionally targets the central nervous system directly via the olfactory pathway. Tmax under 5 minutes, and a robust response at a fraction of the standard oral amount. |
Melatonin research context
Melatonin is one of the best-studied compounds on this catalogue, with a long human safety record. A few points are still worth understanding when reading the literature.
Timing drives the circadian result
Melatonin's phase-shifting effect depends on when it is administered relative to the body clock. Given at the wrong point in the cycle it can shift rhythms in the opposite direction to the one intended — which is why well-designed circadian studies control timing tightly and report it explicitly.
Cell-culture findings are mechanistic, not therapeutic
The oncostatic data comes from cancer cells treated directly in a dish. It is a genuine, reproducible cellular effect and a legitimate reason the compound is studied in oncology — but effects in isolated cells routinely fail to translate to whole organisms, and no claim of treatment benefit follows from it.
Route changes the study, not just the convenience
Because oral bioavailability is as low as 3%, oral and nasal studies are effectively testing very different exposures. Comparing outcomes across routes without accounting for that difference is one of the most common misreadings of the melatonin literature.
Research use only
Material supplied here is strictly for laboratory research and is not for human or veterinary use, regardless of melatonin's regulatory status as a supplement or medicine in any given country.
All information on this page is provided for laboratory and educational reference only. Peptides Lab SA (PTY) Ltd supplies compounds strictly for in-vitro research use. Nothing here is medical advice, a dosing recommendation, or a claim of human safety or efficacy.